Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

Related Citations for PubMed (Select 23306536)

1.

Y402H polymorphism in complement factor H and age-related macular degeneration in the Tunisian population.

Habibi I, Sfar I, Kort F, Aounallah-Skhiri H, Chebil A, Chouchene I, Bouraoui R, Limaiem R, Largheche L, Jendoubi-Ayed S, Makhlouf M, Ben Abdallah T, Ayed K, El Matri L, Gorgi Y.

Ophthalmic Res. 2013;49(4):177-84. doi: 10.1159/000345068. Epub 2013 Jan 10.

PMID:
23306536
2.

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.

Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A.

Ophthalmology. 2007 Dec;114(12):2168-73.

PMID:
18054635
3.

Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.

Nischler C, Oberkofler H, Ortner C, Paikl D, Riha W, Lang N, Patsch W, Egger SF.

Acta Ophthalmol. 2011 Jun;89(4):e344-9. doi: 10.1111/j.1755-3768.2010.02080.x. Epub 2011 Jan 14.

PMID:
21232084
4.

Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.

Kang HK, Yoon MH, Lee DH, Chin HS.

Korean J Ophthalmol. 2012 Dec;26(6):414-22. doi: 10.3341/kjo.2012.26.6.414. Epub 2012 Nov 12.

5.

Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration.

Wegscheider BJ, Weger M, Renner W, Steinbrugger I, März W, Mossböck G, Temmel W, El-Shabrawi Y, Schmut O, Jahrbacher R, Haas A.

Ophthalmology. 2007 Apr;114(4):738-42.

PMID:
17398321
6.
7.

Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population.

Xu Y, Guan N, Xu J, Yang X, Ma K, Zhou H, Zhang F, Snellingen T, Jiao Y, Liu X, Wang N, Liu N.

Mol Vis. 2008 Jul 28;14:1373-81.

8.

Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.

Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr.

Br J Ophthalmol. 2009 May;93(5):610-3. doi: 10.1136/bjo.2008.150995. Epub 2008 Dec 17.

9.

Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.

Smailhodzic D, Muether PS, Chen J, Kwestro A, Zhang AY, Omar A, Van de Ven JP, Keunen JE, Kirchhof B, Hoyng CB, Klevering BJ, Koenekoop RK, Fauser S, den Hollander AI.

Ophthalmology. 2012 Nov;119(11):2304-11. doi: 10.1016/j.ophtha.2012.05.040. Epub 2012 Jul 26.

PMID:
22840423
10.
11.

Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients.

Lau LI, Chen SJ, Cheng CY, Yen MY, Lee FL, Lin MW, Hsu WM, Wei YH.

Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3242-6.

12.

Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population.

Souied EH, Leveziel N, Richard F, Dragon-Durey MA, Coscas G, Soubrane G, Benlian P, Fremeaux-Bacchi V.

Mol Vis. 2005 Dec 19;11:1135-40.

13.

Complement factor H variant Y402H and basal laminar deposits in exudative age-related macular degeneration.

Lommatzsch A, Hermans P, Weber B, Pauleikhoff D.

Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1713-6. Epub 2007 Aug 18.

PMID:
17704937
14.

Association of the HTRA1 -625G>A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population.

Weger M, Renner W, Steinbrugger I, Köfer K, Wedrich A, Groselj-Strele A, El-Shabrawi Y, Schmut O, Haas A.

Mol Vis. 2007 Jul 24;13:1274-9.

15.

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group.

Ophthalmology. 2013 Mar;120(3):593-9. doi: 10.1016/j.ophtha.2012.11.037. Epub 2013 Jan 18.

16.

Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in Koreans.

Kim NR, Kang JH, Kwon OW, Lee SJ, Oh JH, Chin HS.

Invest Ophthalmol Vis Sci. 2008 May;49(5):2071-6. doi: 10.1167/iovs.07-1195. Epub 2008 Jan 25.

17.

Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration.

Feng X, Xiao J, Longville B, Tan AX, Wu XN, Cooper MN, McAllister IL, Isaacs T, Palmer LJ, Constable IJ.

Ophthalmology. 2009 Oct;116(10):1908-12.e1. doi: 10.1016/j.ophtha.2009.03.011. Epub 2009 Aug 18.

PMID:
19692124
18.

Complement factor H Y402H polymorphism and characteristics of exudative age-related macular degeneration lesions.

Seitsonen S, Järvelä I, Meri S, Tommila P, Ranta P, Immonen I.

Acta Ophthalmol. 2008 Jun;86(4):390-4. Epub 2007 Nov 7.

PMID:
17995985
19.

Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.

Kloeckener-Gruissem B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, Michels S, Fleischhauer J, Berger W, Sutter F, Menghini M.

Invest Ophthalmol Vis Sci. 2011 Jul 1;52(7):4694-702. doi: 10.1167/iovs.10-6080.

20.

Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.

Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group).

Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/j.ophtha.2013.03.017. Epub 2013 May 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk